Cargando…
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis
Locoregional treatment with radical intent should be considered during therapy with targeted agents in patients with metastatic renal cell carcinoma (mRCC) in order to achieve a complete response, especially in the setting of an oligo-progression in one or more metastatic sites. We retrospectively e...
Autores principales: | Santini, Daniele, Ratta, Raffaele, Pantano, Francesco, De Lisi, Delia, Maruzzo, Marco, Galli, Luca, Biasco, Elisa, Farnesi, Azzurra, Buti, Sebastiano, Sternberg, Cora Nanette, Cerbone, Linda, Di Lorenzo, Giuseppe, Spoto, Silvia, Sterpi, Michelle, De Giorgi, Ugo, Berardi, Rossana, Torniai, Mariangela, Camerini, Andrea, Massari, Francesco, Procopio, Giuseppe, Tonini, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725056/ https://www.ncbi.nlm.nih.gov/pubmed/29246014 http://dx.doi.org/10.18632/oncotarget.20022 |
Ejemplares similares
-
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
por: Santini, Daniele, et al.
Publicado: (2016) -
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022) -
The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
por: Guida, Michele, et al.
Publicado: (2019) -
Targeting bone metastases starting from the preneoplastic niche: home sweet home
por: Santini, Daniele, et al.
Publicado: (2011) -
Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)